Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.76 |
| ▸ | TK1 | P04183 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982470 | 1.00 | TYMS (0.76) | TYMSTK1LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL13273335 | 1.00 | TYMS (0.76) | TYMSTK1LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL5982466 | 1.00 | TYMS (0.76) | TYMSTK1LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL19777590 | 1.00 | TYMS (0.76) | TYMSTK1LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL5872460 | 1.00 | TYMS (0.76) | TYMSTK1LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL779177 | 0.91 | TYMS (0.73) | TYMSTK1 | |
| SCHEMBL28937859 | 0.90 | LMNA (0.66) | TYMSTK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL5982081 | 0.89 | TYMS (0.61) | TYMSTK1LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL20456162 | 0.88 | TYMS (0.63) | TYMSTK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL30083709 | 0.88 | LMNA (0.65) | TYMSTK1LMNASMN1; SMN2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115611816-A | Method for efficiently preparing 5-aryl (hetero) ring modified uracil derivative | 中国科学院化学研究所 | 2023-01-17 | — | — | CN | disclosed |
| US-10940150-B2 | Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2021-03-09 | — | — | US | disclosed |
| US-20180207160-A1 | THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20170216297-A1 | EFFICIENT INHIBITION OF HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2017-08-03 | — | — | US | disclosed |
| EP-3174545-A1 | EFFICIENT INHIBITION OF HSP27 | Technische Universität Dresden (DE) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016267-A1 | EFFICIENT INHIBITION OF HSP27 | Technische Universität Dresden (DE) | 2016-02-04 | — | — | WO | disclosed |
| US-7057027-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-6962783-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-6875593-B2 | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040265802-A9 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | FROEHLER BRIAN (US) | 2004-12-30 | — | — | US | disclosed |
| EP-0702675-A1 | METHOD FOR PALLADIUM CATALYZED CARBON-CARBON COUPLING AND PRODUCTS | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0702675-A4 | METHOD FOR PALLADIUM CATALYZED CARBON-CARBON COUPLING AND PRODUCTS | UNIV WASHINGTON (US) | 1996-02-02 | — | — | EP | disclosed |
| EP-0637965-A4 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES. | GILEAD SCIENCES INC (US) | 1996-01-24 | — | — | EP | disclosed |
| US-5428149-A | Reacting vinyl and aryl stannanes with 2'-deoxy-5-halo-uridine | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0637965-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1995-02-15 | — | — | EP | disclosed |
| WO-1994029279-A1 | METHOD FOR PALLADIUM CATALYZED CARBON-CARBON COUPLING AND PRODUCTS | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1994-12-22 | — | — | WO | disclosed |
| WO-1993010820-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
| EP-0258412-A1 | COMPOSITION FOR AND METHOD OF TREATING AIDS AND CERTAIN RELATED DISEASES | GREER, Sheldon B. (US) | 1988-03-09 | — | — | EP | disclosed |
| WO-1987004929-A1 | COMPOSITION FOR AND METHOD OF TREATING AIDS AND CERTAIN RELATED DISEASES | GREER SHELDON B | 1987-08-27 | — | — | WO | disclosed |
| US-4210638-A | 5-TRIFLUOROMETHYL-2'-DEOXYCYCTIDINE AND TETRAHYDROURIDINE OR 2'-DEOXYTETRAHYDROURIDINE | PCR, INC. (US) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207160-A1 | THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27 | HSPB1, HSP90B1, HSP90AB1 | TYMS 600/4885TK1 213/4885LMNA 4404/4885 |
| US-20040265802-A9 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | NUDT1, DHX15, DDX5 | TYMS 9/4885TK1 43/4885LMNA 1678/4885 |
| US-20170216297-A1 | EFFICIENT INHIBITION OF HSP27 | HSPB1, HSP90AB2P, HSP90B1 | TYMS 2402/4885TK1 710/4885LMNA 4242/4885 |
| US-10940150-B2 | Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27 | HSPB1, HSP90B1, HSP90AB1 | TYMS 600/4885TK1 213/4885LMNA 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.